Adjuvant anti-PD-1 therapy improves melanoma-specific survival in stage IIIC-IV melanoma patients with high tumor mutation burden and BRAF V600 mutation

Immune checkpoint inhibitors (ICI) have significantly improved melanoma-specific survival (MSS), particularly in patients with tumors with a high tumor mutational burden (TMB) or BRAF mutation. In the adjuvant setting, ICIs significantly improve relapse-free survival (RFS), but data on MSS are still...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Julia Forschner, Julia Huynh, Christopher Schroeder, Sorin Armeanu-Ebinger, Olga Seibel-Kelemen, Axel Gschwind, Irina Bonzheim, Thomas K. Eigentler, Teresa Amaral, Stephan Ossowski, Lukas Flatz, Claus Garbe, Andrea Forschner, Markus Reitmajer
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Frontiers Media S.A. 2025-08-01
Σειρά:	Frontiers in Oncology
Θέματα:	adjuvant immune checkpoint inhibitors relapse-free survival melanoma-specific survival tumor mutational burden BRAF V600E/K mutation
Διαθέσιμο Online:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1618596/full
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!